BenevolentAI
Arpita Ray-Sinha is a Senior Principal Scientist at BenevolentAI, specializing in drug discovery with extensive experience in AI/ML-based target identification programs, particularly in oncology and neuro-degenerative disease areas. Notable accomplishments include leading a small molecule drug discovery program from target identification to pre-IND application. Prior roles include Research Scientist at Kesios Therapeutics and a project focused on drug discovery and target validation at The Institute of Cancer Research, where expertise in cell-based assays and molecular biology techniques was applied to identify biomarkers. Arpita's academic background includes a Master's Degree in Physiology from the University of Liverpool and a Ph.D. in Cell Biology and Biochemistry from The University of Manchester.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.